TFPI Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

TFPI (Tissue Factor Pathway Inhibitor) is a protein coding gene located on human chromosome 2q32.1. TFPI is also known as EPI, TFI, LACI and TFPI1. The human TFPI gene encodes a 35015 Da protein containing 304 amino acids. The TFPI protein is broadly expressed in liver, placenta and other tissues. Among its related pathways are Formation of Fibrin Clot (Clotting Cascade) and Response to elevated platelet cytosolic Ca2+. TFPI is related to serine-type endopeptidase inhibitor activity and peptidase inhibitor activity. TFPI2 is an important paralog of TFPI gene. TFPI is associated with some diseases, including Thrombosis and Hemophilia.

TFPI Protein (3)

    TFPI Antibody (14)

      TFPI ELISA Kit & Match Antibody ELISA Pair Set (3)

      TFPI cDNA Clone (38)


      TFPI Lysate (2)

        More Product Popular With Customers

        TFPI Background

        Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of TF coagulant and signaling activities. It is a Kunitz-type serine proteinase inhibitor that down-regulates tissue factor-initiated blood coagulation. With its Kunitz domains, TFPI exhibits significant homology with human inter-alpha-trypson inhibitor and bovin basic pancreatic trypsin inhibitor. TFPI is the natural inhibitor of TF coagulant and signaling activities. The importance of TFPI in the regulation of blood coagulation is emphasized by how its activity is modulated in human disease. In a factor (F) Xa-dependent feedback system, TFPI binds directly and inhibits the TF-FVII/FVIIa complex. Normally, TFPI exists in plasma both as a full-length molecule and as variably carboxy-terminal truncated forms. TFPI also circulates in complex with plasma lipoproteins. The levels and the dual inhibitor effect of TFPI on FXa and TF-FVII/FVIIa complex offers insight into the mechanisms of various pathological conditions triggered by TF. TFPI may play an important role in modulating TF-induced thrombogenesis and it may also provide a unique therapeutic approach for prophylaxis and/or treatment of various diseases. In addition, studies have shown that TFPI exhibits antiangiogenic and antimetastatic effects in vitro and in vivo. In animal models of experimental metastasis, both circulating and tumor cell-associated TFPI are shown to significantly reduce tumor cell-induced coagulation activation and lung metastasis.

        TFPI References

        • Lwaleed BA, et al. (2006) Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 208(3): 327-39.
        • Amirkhosravi A, et al. (2007) The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost. 33(7): 643-52.
        • Maroney SA, et al. (2008) Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 38(1): 9-14.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.